Pharmacy Services, Tom Baker Cancer Centre, Alberta Health Services, Edmonton, AB, Canada.
Departments of Oncology and Medicine, University of Calgary and Tom Baker Cancer Centre, Alberta Health Services, 1331-29th Street NW, Calgary, AB, T2N4N2, Canada.
Clin Pharmacokinet. 2020 Jan;59(1):7-23. doi: 10.1007/s40262-019-00807-8.
Non-Hodgkin lymphoma (NHL) includes a variety of closely related malignancies that originate from lymphoid precursors. The majority of NHLs are of B-cell lineage, for which traditional therapy involves chemotherapy in combination with the anti-CD20 monoclonal antibody rituximab. Ongoing research into the pathogenesis of NHL subtypes has given rise to the use of novel agents that target specific molecular pathways. While the incidence of NHL extends over a range of ages from pediatric to elderly settings, the majority of diagnoses occur over age 60 years. Increasing the use of concomitant medication coupled with declining organ function among this group of patients creates pharmacokinetic (PK) challenges in administering a number of agents involved in the treatment of NHL. In addition, since many of the new agents are administered orally, there are a number of added PK factors that must be taken into consideration with their prescribing and administration. This article will review the available literature on the PK and pharmacodynamic properties of agents commonly used in the treatment of NHL, and intends to provide information that can assist with properly using these drugs in this setting.
非霍奇金淋巴瘤（NHL）包括多种起源于淋巴前体的密切相关的恶性肿瘤。大多数 NHL 是 B 细胞谱系的，其传统治疗包括化疗联合抗 CD20 单克隆抗体利妥昔单抗。对 NHL 亚型发病机制的持续研究导致了新型药物的使用，这些药物针对特定的分子途径。虽然 NHL 的发病率从儿科到老年人群都有一定的范围，但大多数诊断发生在 60 岁以上。在这群患者中，同时使用多种药物的情况增加，加上器官功能下降，这在 NHL 治疗中涉及的许多药物的药代动力学（PK）管理方面带来了挑战。此外，由于许多新的药物是口服给药的，因此在开处方和给药时必须考虑到许多额外的 PK 因素。本文将回顾常用于 NHL 治疗的药物的 PK 和药效学特性的现有文献，并旨在提供信息，以帮助在这种情况下正确使用这些药物。
